Salt Lake City, Utah-based Echelon Biosciences said this week that it has finalized a license agreement with Lumiphore to use its technology for the development of cancer assays. Echelon said that it would have access to Lumiphore's lanthanide-complex technology, used for research and drug discovery. The technology is useful in new drug development for cancer, diabetes, and inflammation. Financial terms were not disclosed.
Top NewsWednesday, April 5, 2006
Echelon Biosciences, Lumiphore In Licensing Agreement